| Efficacy and Safety of Topical Unpreserved 0.1% Fluorometholone Ophthalmic Solution on Dry Eye Syndrome. |
|
Joon Ho Park, Jun Hun Lee, Young Jeung Park, Hong Kyun Kim |
1Department of Ophthalmology, Kyungpook National University School of Medicine, Daegu, Korea. okeye@knu.ac.kr
2Cheil Eye Hospital, Daegu, Korea. |
| 무방부제성 플루오로메토론 0.1% 점안액의 안구건조증에서의 효과 및 안정성 비교 |
|
박준호1⋅이준훈1⋅박영정2⋅김홍균1 |
Department of Ophthalmology, Kyungpook National University School of Medicine1, Daegu, Korea
Cheil Eye Hospital2, Daegu, Korea |
|
|
| Abstract |
PURPOSE
To evaluate the efficacy and safety of topical unpreserved 0.1% fluorometholone (FML) ophthalmic solution in patients with dry eye syndrome. METHODS: Patients with mild to moderate dry eye syndrome were divided into the control group (Group I), topical unpreserved 0.1% FML group (Group II), and topical preserved 0.1% FML group (Group III). Intraocular pressure (IOP), Ocular Surface Disease Index (OSDI), tear film break-up time (TF-BUT), Oxford stain score (OSS), and tear osmolarity (Tosm) were evaluated at 2 weeks, 4 weeks, 8 weeks, and 12 weeks (Trial 1). Patients with severe dry eye syndrome were divided into 1% methylprednisolone (MP) group (Group I) and 0.1% unpreserved FML group (Group II). Same parameters were evaluated in both groups (Trial 2). RESULTS: In clinical trial I, OSS scores of Group II were lower than other groups (p < 0.05). For severe dry eye patients in clinical trial 2, there were no significant differences in all parameters between the 2 groups. CONCLUSIONS: Topical unpreserved 0.1% fluorometholone was shown to be an effective and relatively safe treatment in patients with dry eye syndrome. |
| Key Words:
Dry eye syndrome;Tear film parameters;Topical unpreserved 0.1% fluorometholone |
|
PDF Links
Full text via DOI
Download Citation
